Trial Profile
Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2012
Price :
$35
*
At a glance
- Drugs Orantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 23 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2011 Planned End Date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 03 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.